

10th November 2016

(1) BSE Ltd
Listing Department
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai 400 001

(2) National Stock Exchange of India Ltd
Listing Department
Exchange Plaza, 5th floor,
Plot no. C/1, G Block,
Bandra Kurla Complex,
Bandra (East), Mumbai - 400 051

Scrip Code: 500087

Scrip Code: CIPLA EQ

(3) SOCIETE DE LA BOURSE DE LUXEMBOURG
Societe Anonyme
35A Boulevard Joseph II,
L-1840 Luxembourg


Dear Sirs,

We are enclosing herewith statement dated 10th November 2016 uploaded by Company's Ugandan subsidiary i.e. Cipla Quality Chemical Industries Limited on its website (www.ciplaqcil.co.ug).

Kindly acknowledge the receipt.

Thank you,

Yours faithfully,
For Cipla Limited



Mital Sanghvi
Company Secretary

Encl: as above



Press Statement

CIPLA QUALITY CHEMICAL INDUSTRIES LTD (CIPLAQCIL) ANNOUNCEMENT OF INTENTION FOR INITIAL PUBLIC OFFERING (IPO)

Uganda, Kampala 10th November, 2016 – As part of its growth strategy, the board of CiplaQCIL is evaluating an Initial Public Offering and Renaissance Capital (Kenya) Limited has been appointed as the official book runner.

Certain shareholders may consider selling down part or all of their stake to enable sufficient free float and liquidity while Cipla Group, represented through its subsidiaries, intends to continue holding the majority stake and control.

Such a transaction would be subject to approval of the relevant market regulators.

-Ends-

About Cipla Quality Chemical Industries Ltd

CiplaQCIL is a state-of-the-art pharmaceutical plant based in Kampala, Uganda focused on production of high quality WHO pre-qualified and affordable life-saving medicines for the SSA region. The portfolio targets three major diseases that are widespread in Uganda and Sub Saharan Africa and comprises Anti-malarials (ACTs), Anti-retrovirals (ARVs) and Hepatitis B drugs. CiplaQCIL has also been approved by regulatory bodies across Africa including: Kenya, Rwanda, Tanzania, Namibia, Ivory Coast, and several others.